此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL

2026年6月28日 更新者:Liping Dou

A Single-arm, Open-label, Phase I Clinical Study of Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL

This prospective study will be conducted in high-risk B-ALL patients post-allo-HSCT. We propose to investigate the safety and therapeutic efficacy of blinatumomab plus low-dose DLI maintenance therapy, with the ultimate goal of enhancing long-term survival outcomes.

研究概览

详细说明

This study is a single-center, prospective, single-arm Phase I clinical trial. Since July 2023, 12 patients with high-risk acute B-lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation were enrolled at the Department of Hematology, the PLA General Hospital . Patients were enrolled after 45d for MSD-HSCT, and after 60d for URD/Haplo donor-HSCT. The maintenance regimen combined blinatumomab (9 µg/day × 7 days) and donor lymphocyte infusion (DLI, CD3+ cells 1× 10⁵/kg). The first cycle was given within the first 3 months after allogeneic HCT and then at approximately 6, 9, and 12 months following transplant. The safety and efficacy of this regimen were analyzed. Patients were premedicated with dexamethasone prior to the start of each cycle. The study was approved by the Ethics Committee of the PLA General Hospital.

研究类型

介入性

注册 (估计的)

60

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Beijing、中国
        • 招聘中
        • Chinese PLA General Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • 1) Voluntary participation: The participant or legal guardian fully understands this clinical study, provides informed consent (ICF), and is willing/able to comply with all trial procedures.

    2) Age: <70 years old at screening, any gender. 3) Diagnosis: High-risk acute B-lymphoblastic leukemia (B-ALL) with MRD-negative status post-transplant. High-risk factors include:

    • >CR1 status
    • Pre-transplant MRD+ status
    • Ph-like subtype
    • KMT2A rearrangement
    • Other high-risk cytogenetic/genetic factors per ELN 2023 criteria. 4) Allergy: No history of severe allergies. 5) Liver function: ALT and AST ≤ 2.5 × ULN; Total bilirubin ≤ 2 × ULN. 6) Renal function: Serum creatinine ≤ ULN. 7) Other conditions: Absence of uncontrolled infections or severe psychiatric disorders.

      8) Performance status: ECOG score 0-3, with life expectancy ≥ 4 months. 9) MRD status: Bone marrow flow cytometry confirmed MRD-negative before enrollment.

      10) Engraftment: Evidence of myeloid and platelet engraftment. 11) GVHD: No active graft-versus-host disease (GVHD).

Exclusion Criteria:

  • 1) Drug hypersensitivity/contraindications: Patients with known allergies or contraindications to the investigational drug(s).

    2) Pregnancy/lactation: Pregnant or breastfeeding female patients. 3) Active infection/GVHD: Patients with active infection or active graft-versus-host disease (GVHD).

    4) Substance abuse: Patients with chronic heavy smoking or alcohol use that may interfere with clinical evaluation.

    5) Impaired consent/compliance: Patients unable to provide informed consent or comply with procedures due to psychiatric/neurological disorders.

    6) Recent major surgery: Patients who underwent major organ surgery within the past 6 weeks.

    7) Organ dysfunction:

  • Liver: ALT or AST > 2.5 × ULN; Total bilirubin > 2 × ULN
  • Kidney: Serum creatinine > ULN 8) Investigator judgment: Patients deemed ineligible by investigators (e.g., poor compliance, substance abuse).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:BLINA+DLI
blinatumomab 9ug d1-7, 28ug d8-14, DLI ( CD3+cell 1×10^5/kg)
blinatumomab 9ug d1-7, 28ug d8-14
CD3+cell 1×10^5/kg

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
1 year progression-free-survival
大体时间:1 year
the percentage of patients who remain alive and whose disease has not gotten relapse one full year after they started treatment.
1 year

次要结果测量

结果测量
措施说明
大体时间
1 year aGVHD rate
大体时间:100 days after transplantation
Number of participants with aGVHD as assessed by acute graft versus host disease grading criteria (refer to Glucksberg criteria) The cumulative incidences of aGvHD was defined as the number and the ratio of the participants with aGVHD.
100 days after transplantation
1 year cGVHD rate
大体时间:365 days after transplantation
Number of participants with cGVHD as assessed by chronic graft versus host disease grading criteria (refer to NIH criteria) cGvHD was diagnosed and graded according to the 2014 National Institutes of Health (NIH) consensus criteria: mild, moderate or severe respectively.
365 days after transplantation
Nonrelapse mortality (NRM)
大体时间:365 days after transplantation
Defined as the proportion of subjects who died due to causes other than malignancy relapse
365 days after transplantation
Overall survival (OS)
大体时间:365 days after transplantation
Defined as the time from study enrollment (first day of ruxolitinib treatment) to death due to any cause
365 days after transplantation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年12月1日

初级完成 (估计的)

2028年11月30日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2026年6月16日

首先提交符合 QC 标准的

2026年6月28日

首次发布 (实际的)

2026年7月1日

研究记录更新

最后更新发布 (实际的)

2026年7月1日

上次提交的符合 QC 标准的更新

2026年6月28日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • BLINADLISTUDY

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅